Mike Milken, chairman of the Milken Institute, has been at the forefront of successful initiatives in medical research, education, public health, and access to capital for more than four decades. Fortune magazine called him "The Man Who Changed Medicine," and Forbes listed him among "Visionaries Reimagining Our Children's Future." In 1982 he formalized his previous philanthropy by co-founding the Milken Family Foundation. The Milken Institute hosts more than 250 events each year, including major conferences in Singapore, London, the Middle East, New York, Los Angeles, and Washington, D.C. The Milken Institute School of Public Health at George Washington University was named to recognize an Institute gift. Milken also chairs FasterCures, which speeds progress against all life-threatening diseases. As a financier, he revolutionized modern capital markets by pricing and rewarding risk more efficiently. The thousands of companies he financed created millions of jobs. A graduate of the University of California, Berkeley, Milken earned his M.B.A. at the Wharton School. He and his wife Lori have been married since 1968 and are members of the Giving Pledge; they have three children and 10 grandchildren. More information is at www.mikemilken.com.
Amy Abernethy serves as chief medical officer, chief scientific officer and senior vice president, oncology, where she leads the research oncology, clinical operations and data science teams, and contributes to the strategic vision of Flatiron Health. Flatiron is a hyper-growth health technology company that started in 2012 and was acquired by Roche Group in 2018 for $2.1 billion.
Before joining Flatiron, Abernethy was professor of medicine at Duke University School of Medicine, and ran the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. For more than a decade, she has pioneered the development of technology platforms to spur novel advancements in cancer care, including the development of systems by which aggregated clinical data can support personalized medicine, outcomes research, cancer care quality monitoring, and scientific discovery.
With over 400 peer-reviewed publications, Abernethy is an internationally recognized expert in clinical trials, cancer outcomes research, health policy, health services research, patient reported outcomes, clinical informatics and patient-centered care. She maintains a close affiliation with Duke, and is a member of the National Academy of Medicine’s National Cancer Policy Forum, past president of the American Academy of Hospice & Palliative Medicine, member of the Board of Directors for the Personalized Medicine Coalition, and recent leader within several federally-funded research networks. She also serves on the Board of Directors for athenahealth (NASDAQ: ATHN) and CareDx (NASDAQ: CDNA) and advises several early-stage health technology companies (SignalPath, Inc; The One Health Company; RobinCare).
Abernethy received her MD at Duke University, where she also did her internal medicine residency, served as chief resident and completed her hematology/oncology fellowship. She has her PhD from Flinders University in Australia, focused on evidence-based medicine and clinical informatics, and her Bachelor’s degree from the University of Pennsylvania.
Margaret Anderson is a managing director with Monitor Deloitte based in Arlington. At Deloitte, she is focused on bringing forward her experience with external trends and patient engagement to our health and medical research practice, our nonprofit work, and commercial life sciences engagements. She is also focused on strengthening nonprofit organizations through strategic planning and organizational assessments. She joined Deloitte from FasterCures, a center of the Milken Institute. While at FasterCures, she oversaw programs advancing the science of patient input, examining the metrics for collaborative research models, and policy related to federal research and regulatory agencies. She has also worked on public health issues at the American Public Health Association and in a consulting capacity for HIV/AIDS programs. She began her career at the Congressional Office of Technology Assessment looking at the impact of biotechnology and genetics on the economy and society. Anderson is a founding board member and past-president of the Alliance for a Stronger FDA, and was a founding member of the National Institutes of Health’s National Center for Advancing Translational Sciences Advisory Council and the Cures Acceleration Network Review Board. She served previously on the National Health Council board, United for Medical Research board, the Food and Drug Administration's Science Board, Science Looking Forward Committee, and the National Academy of Medicine’s Forum on Drug Discovery, Development and Translation. She currently serves on the board of Act for NIH, the Asthma and Allergy Foundation of America, and the Melanoma Research Alliance.
David Baltimore is a professor of biology at the California Institute of Technology and the 1975 Nobel Prize recipient for work in virology. Among his accomplishments, Baltimore was founding director of MIT's Whitehead Institute for Biomedical Research, president of Rockefeller University, and head of the National Institutes of Health’s AIDS Vaccine Research Committee. He helped create a consensus on national science policy regarding recombinant DNA research and established standards for genetic research. Baltimore also earned the 1970 Gustave Stern award in virology, the 1971 Eli Lilly and Co. award in microbiology and immunology, the 1999 National Medal of Science, and the 2000 Warren Alpert Foundation Prize. He earned his doctorate at Rockefeller University.
Tanisha Carino is a respected senior executive with more than two decades of experience in academia, government, and the private sector. She joined the Milken Institute in January 2018 as executive director of FasterCures, the center devoted to saving lives and improving the medical research system. Throughout her distinguished career, Carino has been at the forefront of collaborative efforts to promote policies, research, and business practices that support the fight against disease and improve the lives of patients. She most recently led the U.S. policy function for GlaxoSmithKline, a U.K.-based global health-care company. Prior to her role at GlaxoSmithKline, she spent more than a decade with Avalere Health, where, among other responsibilities, she founded the Center on Evidence Based Medicine and worked with patients, government, and senior leaders at Fortune 500 companies to maximize opportunities and mitigate challenges related to biomedical research and patient access. Prior to Avalere, Carino worked in the Medicare program to improve access for its beneficiaries and support the development of real-world evidence. Carino serves on the boards of the Alliance for Health Policy, the Medical Device Innovation Consortium, the Institute for Clinical and Economic Review, and Bread for the City. She is also a member of the Drug Information Association’s Patient Group Advisory Council and Women of Impact. Carino holds a B.A. in sociology from Emory University in Atlanta and a Ph.D. in health policy from Johns Hopkins University in Baltimore. She is an associate faculty member at the Johns Hopkins Bloomberg School of Public Health and a Fulbright fellow.
David Feinberg is president and CEO of Geisinger, one of the nation’s most innovative health services organizations, which includes 13 hospital campuses, a nearly 600,000-member health plan, two research centers and a school of medicine that serve and care for over 3 million residents in Pennsylvania and New Jersey. With a focus on caring for patients and members, Feinberg launched SpringBoard Health®, a population health initiative to improve the health of an entire community; Geisinger’s ProvenExperience™, to provide refunds to patients unhappy with their care experience; and Geisinger’s MyCode® Community Health Initiative, the largest health-care system-based precision health project in the world that is integrating medically actionable results in routine clinical care while conducting extensive research. To date, nearly 200,000 volunteer participants have enrolled. Prior to joining Geisinger, Feinberg served as CEO of UCLA’s hospitals and associate vice chancellor of UCLA Health Sciences, as well as president of UCLA Health System. Recognized nationally as a top health-care leader, Modern Healthcare ranked Feinberg third on the 2018 Most Influential Physician Executives and Leaders list for the second year in a row. He is also listed among Modern Healthcare’s 100 Most Influential People in Healthcare and Becker Hospital Review’s 100 Great Leaders in Healthcare. Feinberg earned his undergraduate degree at the University of California, Berkeley. He graduated with distinction from the University of Health Sciences/Chicago Medical School. He earned a Master of Business Administration from Pepperdine University.
Margaret Hamburg is an internationally recognized leader in public health, medicine, and science. She is president of the American Association for the Advancement of Science, as well as the foreign secretary for the National Academy of Medicine. Formerly, Hamburg was commissioner of the U.S. Food and Drug Administration, known for advancing regulatory science, modernizing regulatory pathways, and globalization of the agency. Before this, she was founding vice president and senior scientist at the Nuclear Threat Initiative, a foundation dedicated to reducing nuclear, chemical and biological threats. Other positions have included assistant secretary for planning and evaluation, U.S. Department of Health and Human Services; health commissioner for New York City; and assistant director of the National Institute of Allergy and Infectious Disease, National Institutes of Health. Hamburg currently serves on numerous boards and advisory committees. She is a graduate of Harvard College and Harvard Medical School.
Annalisa Jenkins, M.B.B.S., F.R.C.P., president and CEO at a leading cardiovascular liquid biopsy diagnostics company, Plaquetec Therapeutics, is a biopharma thought leader with over 20 years of industry experience. Jenkins has extensive recent experience in building and financing biotech companies pursuing cures for the most challenging rare diseases to address important medical issues globally. She has consistently built and led teams advancing programs from scientific research through clinical development, regulatory approval, and into health-care systems globally. In addition, she is an advocate for diversity and inclusion, particularly for women in science. Prior to joining Plaquetec in November 2017, Jenkins served as president and CEO of Dimension Therapeutics, a leading gene therapy company that she took public on the NASDAQ and subsequently sold to Ultragenyx. Prior senior leadership roles have included the head of global research and development at Merck Serono Pharmaceuticals from 2013 to 2014, where she also served as executive vice president global development and medical from 2011 to 2013, and several leadership roles at Bristol Myers-Squibb from 1997 to 2011, most recently serving as senior vice president and head of global medical affairs. Earlier in her career, Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.
Freda Lewis-Hall serves as Pfizer’s chief medical officer and leads Pfizer Medical, the division responsible for the safe, effective, and appropriate use of Pfizer medicines and vaccines around the world. Besides providing science-grounded medical information to prescribers and patients, Pfizer
Medical is also responsible for the company’s office of patient affairs, its centers of excellence on pediatric care, clinical trial diversity and healthy aging, its enterprise benefit-risk communications, its worldwide compassionate access program as well as driving innovative public-private partnerships. Before joining Pfizer in 2009, Lewis-Hall held senior leadership positions in medical affairs and product development with Vertex, Bristol-Myers Squibb, Pharmacia, and Eli Lilly and Company. Prior to joining the biopharmaceutical industry, she served as vice chairperson and associate professor in the Department of Psychiatry at Howard University College of Medicine and was an advisor to the
National Institute of Mental Health. Lewis-Hall graduated from Johns Hopkins University and earned her medical doctorate at Howard University College of Medicine. She launched her medical career as a practicing physician and then focused her academic research on the effects of health-care disparities and the impact of mental illness on families and communities. Lewis-Hall is a Distinguished Fellow of the American Psychiatric Association. Lewis-Hall currently serves on the boards of SpringWorks Therapeutics, Dell Medical School at the University of Texas at Austin, Harvard Medical School, the Foundation for the National Institutes of Health, and the Patient-Centered Outcomes Research Institute.
Mark McClellan is the Robert J. Margolis Professor of Business, Medicine, and Policy, and founding director of the Duke-Margolis Center for Health Policy at Duke University. McClellan is a doctor and an economist who has addressed a wide range of strategies and policy reforms to improve health care, including payment reform to promote better outcomes and lower costs, methods for development and use of real-world evidence, and strategies for more effective biomedical innovation. Before coming to Duke, he served as a senior fellow in economic studies at the Brookings Institution, where he was director of the Health Care Innovation and Value Initiatives and led the Richard Merkin Initiative on Payment Reform and Clinical Leadership. McClellan is a former administrator of the Centers for Medicare & Medicaid Services and former commissioner of the U.S. Food and Drug Administration, where he developed and implemented major reforms in health policy. McClellan is the founding chair and a current board member of the Reagan-Udall Foundation for the FDA and is a member of the National Academy of Medicine. He is also a senior advisor on the faculty of the University of Texas Dell Medical School and is an independent director on the board of Johnson & Johnson and on the board of Alignment Healthcare. He was previously an associate professor of economics and medicine with tenure at Stanford University, and has twice received the Kenneth Arrow Award for Outstanding Research in Health Economics.
Shmuel Meitar is co-founder of the Aurec Group, which has a 40-year record of building companies from inception to maturity. His legacy includes Amdocs, the world leader in customer care and billing software; Yellow Pages; companies in the cable TV, telecommunications, outdoor advertising, insurance, and financial investments fields; and real estate. Aurec has developed successful long-term partnerships with Blue Chip International as well as local firms. Its partners have included AT&T, as well as AIG, newspapers, and Israel’s leading bank. In recent years, Aurec Group has phased out of the majority of its operating businesses, and it now manages its investments through private holding companies. Aurec Group is currently one of Israel’s leading and most reputable investment groups. Meitar is the founder of Time to Know, the first comprehensive digital teaching platform, which was founded in 2005 by experts in pedagogy and technology. Meitar is also involved in supporting medical research, including serving on the boards of FasterCures and the Prostate Cancer Foundation in the United States and sponsoring research at the Weizmann Institute of Science and by Nobel laureates. Meitar has been a member of the International Advisory Council of the Brookings Institution since 2015.
Dan Mendelson is founder of Avalere Health, a vibrant community of innovative thinkers dedicated to solving the challenges of the health-care system through data-driven advisory services and business intelligence products. Mendelson founded the group in 2000, brought in ABS Capital as a minority investor in 2008, and grew the company organically as CEO to span a community of 250 staff. In 2015, Mendelson sold Avalere to Inovalon Holdings and continued to operate the firm through the end of 2017. He now serves as an advisor to the company. From 1998 to 2000, Mendelson served as associate director for health at the Office of Management and Budget (OMB) in the Clinton White House. He was responsible for the full health-care portfolio including Medicare, Medicaid, National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. Prior to joining OMB, Mendelson was senior vice president of The Lewin Group and director of the medical technology practice. Between 1994 and 1996, Mendelson was also closely involved in the operations of Value Rx, a pharmacy benefit management company. He also actively assisted both Value Health and Quintiles Transnational in due diligence on acquisitions. Mendelson has published widely in peer-reviewed journals on health information technology, the costs of disease, hospital costs and operations, physician payment, the economics of managed care, and medical malpractice. He holds an undergraduate degree in economics and viola performance from Oberlin College and a Master’s in Public Policy from the Kennedy School of Government at Harvard University.
Richard Merkin is the CEO and founder of the Heritage Group. Under his stewardship, the Heritage Group has become the largest, physician-owned and -operated integrated delivery system in the United States with more than 50 related health-care companies. The Heritage Group encompasses numerous patent, venture capital, private equity, and insurance companies. Merkin serves on the board of the California Institute of Technology and the Keck School of Medicine at the University of Southern California (USC). He is a founding board member of FasterCures. He has established the Richard Merkin Foundation for Stem Cell Research at the Broad Institute at Harvard and the Massachusetts Institute of Technology, the Richard Merkin Initiative at the Johns Hopkins Brain Sciences Institute, the Richard Merkin Foundation for Neural Regeneration at UCLA, and the Merkin Family Foundation Fund for Regenerative Medicine at the Keck School of Medicine at USC. He is on the board of the California Nano Systems Institute and serves on many other boards that focus on science, health care, and finance. Inspired by the X-Prize Foundation, Merkin launched the Heritage Health Prize, a $3 million global incentivized competition seeking to achieve a fundamental breakthrough in our ability to predict future hospitalization. Merkin supports the Merkin initiative to study payment and clinician reform at the Brookings Institution in Washington, DC.